|

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

RECRUITINGEarly 1Sponsored by University of Oklahoma
Actively Recruiting
PhaseEarly 1
SponsorUniversity of Oklahoma
Started2023-12-01
Est. completion2026-09
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT05921253

Summary

This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients (\>18 years) who have received anthracycline-based therapy for breast cancer or lymphoma within the last 30 days
* A least 1 of following additional criteria:

  * previous chest radiation

    . Age\>50
  * type 2 diabetes mellitus
  * hypertension
  * current smoking
  * obesity (BMI ≥ 30)
  * previous myocardial infarction
  * established atherosclerotic heart disease or significant valve disease. chronic kidney disease

Exclusion Criteria:

* Atrial paced rhythm
* History of seizure currently on treatment
* History of vasovagal syncope
* End stage liver or kidney disease

Conditions3

Breast CancerCancerLymphoma

Locations2 sites

Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104
SCC IIT Office405-271-8777SCC-IIT-Office@ouhsc.edu
Stephenson Cancer Center- Tulsa
Tulsa, Oklahoma, 74104
Lead NurseSCC-IIT-Office@ouhsc.edu

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.